Neoplasms

Digestive System Diseases

All Conditions

Skin and Connective Tissue Diseases

Rare Diseases

Gastrointestinal Stromal Tumors

Neoplasms, Connective Tissue

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Apatinib

Angiogenesis Inhibitors

Sunitinib

Dasatinib

Tyrosine Kinase Inhibitors

Imatinib Mesylate

Growth Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Subjects received TKI second-line therapy such as Sunitinib, Imatinib plus, Dasatinib, and Reveratinib.

Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect of anti-C-Kit and PDGFR.

Apatinib Mesylate

Sunitinib, Imatinib dosage, Dasatinib, Reveratinib

Gang Cheng, Ph.D

Heli Liu, Ph.D

The goal of this Mesylate apatinib versus standard second-line TKI in the treatment of advanced gastrointestinal stromal tumors: a randomized, open, controlled, single-center clinical study is to explore the efficacy and safety of Apatinib compared with second-line treatment in advanced GIST patients with first-line TKI failure. The main questions it aims to answer are:

* To explore the efficacy and safety of Apatinib compared with standard second-line treatment for GIST with advanced first-line TKI failure.
* To explore the expression level and MVD value of VEGFR2 in GIST, and to explore the relationship between the expression level and the location, size, mitotic image and recurrence risk grading of GIST.

Patients with advanced GIST were randomly included in the trial group and the control group at a ratio of 1:1.

The objectives of this study were as follows:

1. To explore the efficacy and safety of Apatinib compared with standard second-line treatment of advanced GIST with first-line TKI failure, and to provide high-level clinical evidence for the treatment of late-stage plasmatoma;
2. Explore the expression level and MVD value of VEGFR2 in GIST, and explore the relationship between the expression level and the location, size, mitotic image and recurrence risk grading of GIST.

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced Gastrointestinal Stromal Tumors: a Randomized, Open, Controlled, Single-center Clinical Study

Progression-free survival is the time from treatment to observed disease progression or death from any cause.

Overall Survival is the time from randomization to death from any cause.For subjects who had been lost to follow-up prior to death, the last follow-up time was usually calculated as the time of death.

Objective response rate refers to the proportion of patients whose tumor volume has decreased to a predetermined value and can maintain the minimum time limit, including complete response (CR) and partial response (PR) cases.

Disease control rate (DCR) refers to the proportion of patients whose tumors shrink or stabilize for a certain period of time, including complete response (CR), partial response (PR), and stable disease (SD) cases.

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Xiangya Hospital of Central South University

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST	NCT05751733	Gastrointestina...	Apatinib Mesyla... Sunitinib, Imat...	18 Years -	Xiangya Hospital of Central South University
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST	NCT05751733	Gastrointestina...	Apatinib Mesyla... Sunitinib, Imat...	18 Years -	Xiangya Hospital of Central South University

Spots Global Cancer Trial Database for sunitinib, imatinib dosage, dasatinib, reveratinib